Have people really considered what they are interviewing for?

Quote

Anonymous

Guest
Abilify Maintenna currently has 1.5% marketshare in the LAI marketplace. JNJ has eaten Otsuka's lunch since day one. MD's never believed in Abilify for schizophrenia and they still don't. Once again everyone is clammering to interview for a job in which the company has never commercialized a product, they have piss poor management and marketing not to mention zero ability to track these prescriptions to these specialty pharmacies. Folks this is a feast or phamon job, either get it or get out. All of this while JNJ is bringing their longer acting market leader to market. Good luck, do your research before you decide to jump. Could be the shortest experience of your life for many reasons.
 






Please, AM has a 1.5% share cause of Haldol Dec. No branded LAI has a market share greater than 4%...Yet, each one is pulling $100mils. Arip is a so so antipysch for schiz, but it is still used in that market with good results. You should talk to your MD's about that, if they aren't telling you, then you shouldn't be interviewing for this job.

Please explain to me how any branded company is tracking LAI Rx to pharmacies, cause IMS cant do that.

Yes, JNJ will have a longer injection, but so will Alk. The difference is Otsuka has nothing in pipeline, but Alk does. If you do any research, Alk knows how long this will take. There is a reason its not in someone else's hands.

Good luck to you,
 


















What part of the post don't you understand. This is a company that has no experiencing bringing a drug to market. If the drug is approved, historically the molecule (tab or injection) has little or no market share in Schizophrenia. The branded LAI marketplace is only worth a $1B. So what this all means, your career at ALKS could be short lived.
 






Anonymous said:
Abilify Maintenna currently has 1.5% marketshare in the LAI marketplace. JNJ has eaten Otsuka's lunch since day one. MD's never believed in Abilify for schizophrenia and they still don't. Once again everyone is clammering to interview for a job in which the company has never commercialized a product, they have piss poor management and marketing not to mention zero ability to track these prescriptions to these specialty pharmacies. Folks this is a feast or phamon job, either get it or get out. All of this while JNJ is bringing their longer acting market leader to market. Good luck, do your research before you decide to jump. Could be the shortest experience of your life for many reasons.
Click to expand...

Hey, Idiot..... The term is "feast or famine". What the hell is a "phamon"???? STFU.
 


















Anonymous said:
aripiprazole lauroxil could be shown to be unsafe or ineffective; and those risks described in the Alkermes plc Annual Report on Form 10-K
Click to expand...
So tell that to all the other companies that have drugs waiting for approval: Novartis, Merck, Amgen, Lundbeck, Clovis, Tesaro, Janseen, etc.
It is a part of the business!
 






Anonymous said:
What part of the post don't you understand. This is a company that has no experiencing bringing a drug to market. If the drug is approved, historically the molecule (tab or injection) has little or no market share in Schizophrenia. The branded LAI marketplace is only worth a $1B. So what this all means, your career at ALKS could be short lived.
Click to expand...

2 things

1) You do know that Janssen has 2 $1bil branded LAIs.

2) Alk manufactures and owns the technology for those...

You need to do your homework before you start claiming things that you know nothing about.
 






Anonymous said:
Abilify Maintenna currently has 1.5% marketshare in the LAI marketplace. JNJ has eaten Otsuka's lunch since day one. MD's never believed in Abilify for schizophrenia and they still don't. Once again everyone is clammering to interview for a job in which the company has never commercialized a product, they have piss poor management and marketing not to mention zero ability to track these prescriptions to these specialty pharmacies. Folks this is a feast or phamon job, either get it or get out. All of this while JNJ is bringing their longer acting market leader to market. Good luck, do your research before you decide to jump. Could be the shortest experience of your life for many reasons.
Click to expand...

Yes. You are right when you state that physicians don't see Abiify as a very good product for schizophrenia, but I think Alkermes knows that their product will do about as well as Abilify Maintenna. IF they don't understand that then this will be a difficult company to work for. I think the positive about Alkermes is that they have a great pipeline with two great drugs coming out about a year after their LAI Abilify. That's why I am interviewing and would take the job if offered to me. The LAI Abilify will be a dog to promote but I think it is just a place holder for the company until the real drugs are approved and launched in this space the MDD and the other antipsychotic that are coming. I'm willing to take the risk for a big payoff when the MDD drug is approved an launched. Until then, I can stomach selling the LAI Abilify .
 






Anonymous said:
Yes. You are right when you state that physicians don't see Abiify as a very good product for schizophrenia, but I think Alkermes knows that their product will do about as well as Abilify Maintenna. IF they don't understand that then this will be a difficult company to work for. I think the positive about Alkermes is that they have a great pipeline with two great drugs coming out about a year after their LAI Abilify. That's why I am interviewing and would take the job if offered to me. The LAI Abilify will be a dog to promote but I think it is just a place holder for the company until the real drugs are approved and launched in this space the MDD and the other antipsychotic that are coming. I'm willing to take the risk for a big payoff when the MDD drug is approved an launched. Until then, I can stomach selling the LAI Abilify .
Click to expand...
So you are gonna make your nut on an MDD drug, Only 2% of the market is left to sell a branded MDD product. Managed Care prevents any more big ticket billion dollar drugs in generic markets like depression and schizophrenia. One gigantic step edit! You will get your ,25 percent of the branded market.
 






And this is why you have un treated patients suffering from mental illness killing off 150 people on airplanes. We can either try and be part of the solution and affect change, OR allow this to continue. I'm going with change.
 






Anonymous said:
And this is why you have un treated patients suffering from mental illness killing off 150 people on airplanes. We can either try and be part of the solution and affect change, OR allow this to continue. I'm going with change.
Click to expand...

And you sir don't know anything about mental illness! Good luck with trying to change this.
 






As I'm poster #2, Ill give my thoughts post interview....

This is a company that will try and piggy back on others hard work. Laorxil might have some serious drawbacks, which you can research yourself. Between SE and Abilify this will be a hard sale. Granted, they seem to expect that.

On that note, I highly doubt that Alk knows anything about this market. I and numerous other experienced reps in LAI have all had flags raised during the interview process. Alk has taken on too many managers, office staff, and directors with little to no injection experience to understand the challenges in this market. There is a reason that $$$$$ is offered, but it might be short lived.

Alk will continue to generate revenue from Consta, Sustenna, but the Laorxil will never match the revenue from these licensed products. This begs the question whether Alk's upper management will spin off the pipeline.

Best of luck to anyone that take offers
 






Anonymous said:
As I'm poster #2, Ill give my thoughts post interview....

This is a company that will try and piggy back on others hard work. Laorxil might have some serious drawbacks, which you can research yourself. Between SE and Abilify this will be a hard sale. Granted, they seem to expect that.

On that note, I highly doubt that Alk knows anything about this market. I and numerous other experienced reps in LAI have all had flags raised during the interview process. Alk has taken on too many managers, office staff, and directors with little to no injection experience to understand the challenges in this market. There is a reason that $$$$$ is offered, but it might be short lived.

Alk will continue to generate revenue from Consta, Sustenna, but the Laorxil will never match the revenue from these licensed products. This begs the question whether Alk's upper management will spin off the pipeline.

Best of luck to anyone that take offers
Click to expand...

Alkermes success totally depends on their success contracting it to the Medicaid and Medicare Part D plans. Alkermes will sell it on price or they won't succeed! It's no more complicated than that! If Otsuka doesn't play ball and contract Maintena then they will give the hard work of two sales forces and two years of work away with the stroke of a pen . A bunch of I'll trained Latuda reps don't have a clue . The LAI reps that leave will either wish to hell they stayed put or will look like geniuses that they left! Roll the dice! Snake Eyes you lose!
 






Anonymous said:
Alkermes success totally depends on their success contracting it to the Medicaid and Medicare Part D plans. Alkermes will sell it on price or they won't succeed! It's no more complicated than that! If Otsuka doesn't play ball and contract Maintena then they will give the hard work of two sales forces and two years of work away with the stroke of a pen . A bunch of I'll trained Latuda reps don't have a clue . The LAI reps that leave will either wish to hell they stayed put or will look like geniuses that they left! Roll the dice! Snake Eyes you lose!
Click to expand...

As I said, go research the difference between the two products! It's not just about contracts, which I don't think alk is playing. Also, cost of failed injection will play into the contract. 60% site reaction in Delt on a so so molecule means more then one patient isn't going to dance wth this. How many clinics will it take to bitch to your managed care or bhos to get AM back into position.

Good luck to everyone,
 












Anonymous said:
What part of the post don't you understand. This is a company that has no experiencing bringing a drug to market. If the drug is approved, historically the molecule (tab or injection) has little or no market share in Schizophrenia. The branded LAI marketplace is only worth a $1B. So what this all means, your career at ALKS could be short lived.
Click to expand...

You shits are toast!!!
 






Anonymous said:
Alkermes success totally depends on their success contracting it to the Medicaid and Medicare Part D plans. Alkermes will sell it on price or they won't succeed! It's no more complicated than that! If Otsuka doesn't play ball and contract Maintena then they will give the hard work of two sales forces and two years of work away with the stroke of a pen . A bunch of I'll trained Latuda reps don't have a clue . The LAI reps that leave will either wish to hell they stayed put or will look like geniuses that they left! Roll the dice! Snake Eyes you lose!
Click to expand...

LAtuda, your tuda!
 






Top Bottom
Back
Quote